Venous thromboembolism in women: A specific reproductive health risk

Human Reproduction Update

Volumn 19, Issue 5, 2013, Pages 471-482

  Eichinger, S ^a   Evers, J L H ^b   Glasier, A ^c   La Vecchia, C ^d,e   Martinelli, I ^f   Skouby, S ^g,h   Somigliana, E ^f   Baird, D T ^c   Benagiano, G ⁱ   Crosignani, P G ^f   Gianaroli, L ^j   Negri, E ^d   Volpe, A ^k  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j SISMeR   (Italy)

^k UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

more..

Author keywords

Hormonal contraception; Hormone replacement therapy; Ovarian hyperstimulation; Pregnancy; Venous thromboembolism

Indexed keywords

DESOGESTREL; DROSPIRENONE; GESTODENE; LEVONORGESTREL;

ARTICLE; BLOOD CLOTTING; BODY WEIGHT; CARDIOVASCULAR RISK; DEATH; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; MENOPAUSE; MORBIDITY; OVARY HYPERSTIMULATION; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; REPRODUCTIVE HEALTH; SEX DIFFERENCE; THROMBOPHILIA; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

HORMONAL CONTRACEPTION; HORMONE REPLACEMENT THERAPY; OVARIAN HYPERSTIMULATION; PREGNANCY; VENOUS THROMBOEMBOLISM;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CONTRACEPTION; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; INFERTILITY, FEMALE; MALE; MIDDLE AGED; OVULATION INDUCTION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PULMONARY EMBOLISM; REPRODUCTIVE HEALTH; RISK FACTORS; SEX FACTORS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84882735270     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmt028     Document Type: Article

References (99)

1. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003;89:493-498.
2. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117:93-102.
3. Allman-Farinelli MA. Obesity and venous thrombosis: a review. Semin Thromb Hemost 2011;8:903-907.
4. Anderson FA, Wheeler HB, Goldberg RJ, HosmerDW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991;151:933-938.
5. Bagot CN, Arya R. Virchowand his triad: a question of attribution. Br J Haematol 2008; 143:180-190.
6. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvick PO. VTE, thrombophilia, antithrombotic therapy and pregnancy. Antithrombotic therapy and prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012;141:e691S-e736S.
7. Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U, Harenberg J, Herchenhan E, Keller F, Kemkes-Matthes B et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007;98:1237-1245.
8. Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ 2013;185:E115-E120.
9. Bourjeily G, Paidas M, Khalil H, Rosene-Montella K, Rodger M. Pulmonary embolism in pregnancy. Lancet 2010;375:500-512.
10. Bucciarelli P, Mannucci PM. The hemostatic system through aging and menopause. Climacteric 2009;12(Suppl. 1):47-51.
11. Chan WS. The 'ART' of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol 2009;21:207-218.
12. Chan WS, Dixon ME. The 'ART' of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res 2008; 121:713-726.
13. Chen MM, Coakley FV, Kamal A, Loros RK Jr. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol 2008;112(2 Pt 1):333-340.
14. Chunilal SD, Eikelboom JW, Attia J, Miniati M, Panju AA, Simel DL, Ginsberg JS. Does this patient have pulmonary embolism? JAMA 2003;290:2849-2858.
15. CMACE, Centre for Maternal and Child Enquiries. Saving mothers' lives. reviewing maternal deaths to make motherhood safer: 2006-2008. BJOG 2011;118(Suppl. 1):1-205.
16. CSM. Cypoterone acetate (Dianette): risk of venous thromboembolism (VTE). Curr Prob Pharmacovigil 2002;28:9-10.
17. D'AngeloA. Ovarian hyperstimulationsyndrome prevention strategies: cryopreservation of all embryos. Semin Reprod Med 2010;28:513-518.
18. DeStefanoV, Martinelli I, Rossi E, BattaglioliT, Za T, Mannucci PM, Leone G. The risk of recurrent venous thromboembolism in pregnancy and puerperium withoUT antithrombotic prophylaxis. Br J Haematol 2006;135:386-391.
19. Dinger JC, Heinemann LAJ, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-354.
20. Dorflinger LJ. Metabolic effects of implantable steroid contraceptives for women. Contraception 2002;65:47-62.
21. Egberg N, van Beek A, Gunnervik C, Hulkko S, Hirvonen E, Larsson-Cohn U, Bennink HC. Effects on the haemostatic system and liver function in relation to Implanon and Norplant. A prospective randomized clinical trial. Contraception 1998;58:93-98.
22. Eichinger S, Weltermann A, Philipp K, Hafner E, Kaider A, Kittl EM, Brenner B, Mannhalter C, Lechner K, Kyrle PA. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost 1999;82:1232-1236.
23. Eischer L, Tscholl V, Heinze G, Traby L, Kyrle PA, Eichinger S. Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study. PLoS One 2012;7:e38705.
24. European Medicines Agency. EMA update on Diane 35 (cyproterone acetate 2mg, ethinylestradiol 35mcg) and generics for treatment of acne following French decision to suspend marketing authorization, January 2013. http://www.ema. europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/01/news_ detail_001703.jsp&mid=WC0b01ac058004d5c1.
25. FDA, U.S. Food and Drug Administration, 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm273 039.htm.
26. Garattini S, Bertele V. Adjusting Europe's drug regulation to public health needs. Lancet 2002;358:64-67.
27. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379:1835-1846.
28. Goldstein J, Cushman M, Badger GJ, Johnson JV. Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study. Fertil Steril 2007;87:1267-1270.
29. Goodacre S, Sampson F, Thomas S, van Beek E, Sutton A. Systematic review and meta-analysis of the diagnostic accuracy of ultrasonography for deep vein thrombosis. BMC Med Imaging 2005;5:6.
30. Hannaford PC. The progestogen content of combined oral contraceptives and venous thromboembolic risk. BMJ 2011;343:d6592.
31. Hansen AT, Kesmodel US, Juul S, Hvas AM. No evidence that assisted reproduction increases the risk of thrombosis: a Danish national cohort study. Hum Reprod 2012;27:1499-1503.
32. Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999;4:67-73.
33. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006;21: 23-29.
34. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005;143:697-706.
35. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003;29:125-130.
36. Henriksson P, Westerlund E, Wallen H, Brandt L, Hovatta O, Ekbom A. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ 2013;346:e8632.
37. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebocontrolled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-967.
38. ICSI (Institute for Clinical Systems Improvement). http://www.icsi.org/knowledge/detail.asp?catID=29&itemID=202 (10 May 2012, date last accessed). Inman WH, VesseyMP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. BMJ 1970;2:203-209.
39. Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 6:905-912.
40. Jaffer AK. An overview of venous thromboembolism: impact, risks, and issues in prophylaxis. Cleve Clin J Med 2008;75(Suppl. 3):S3-S6.
41. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006;194:1311-1315.
42. JeremiahZA, Adias TC, Opiah M, George SP, MgbereO, Essien EJ. Elevation in D-dimer concentrations is positively correlated with gestation in normal uncomplicated pregnancy. Int J Womens Health 2012;4:437-443.
43. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case- control analysis. BMJ 2000;321:1190-1195.
44. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350:2558-2563.
45. Legnani C, Palareti G, Guazzaloca G, Cosmi B, Lunghi B, Bernardi F, Coccheri S. Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. Eur Heart J 2002;23:984-990.
46. Lenzer J. Waringins on two birth control pills are too weak, FDA panel rules. BMJ 2011; 343:1227.
47. Lidegaard O, Loøkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890.
48. Lidegaard O, Nielsen LH, Skovlund CV, Skjeldestad FE, Loøkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343:d6423.
49. Lidegaard O, Milsom I, Geirsson RT, Skjeldestad FE. Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand 2012a;91:769-778.
50. Lidegaard O, Nielsen LH, SkovlundCW, Loøkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012b; 344:e2990.
51. Lindqvist PG, Hellgren M. Is obstetric thromboprophylaxis with low-molecular-weight heparin effective? Yes, if administered properly. J Thromb Haemost 2011; 9:1669-1670.
52. Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall-Pedoe H. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997;97:775-784.
53. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012;345:e4944.
54. Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002;87:791-795.
55. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994;50(Suppl. 1):S1-195.
56. Medicines and Healthcare Products Regulatory Agency. Hormone replacement therapy. Updated advice. Drug Safety Update 2007;1:2-6.
57. Mostbeck A. Die Inzidenz von Lungenembolien bei venosen Thrombosen. Wien Med Wochenschr 1999;149:72-75.
58. Mozes M, Bogokowsky H, Antebi E, Lunenfeld B, Rabau E, SerrDM, David A, Salomy M. Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. Lancet 1965;2:1213-1215.
59. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstroøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-699.
60. Nelson SM. Prophylaxis of VTE in women-during assisted reproductive techniques. Thromb Res 2009;123(Suppl. 3):S8-S15.
61. NICE (National Institute on Clinical Excellence). Venousthromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing; NICE Clinical Guideline No. 144. http://www.nice.org.uk/nicemedia/live/13767/59711/59711.pdf (26 February 2013, date last accessed).
62. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992;232:155-160.
63. Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008. Am J Obstet Gynecol 2012;207:377.e1-377.e8.
64. Olie V.,Canonico M.,Scarabin P.Y.;Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women:Curr Opin Hematol:2010:17;457-463.
65. Olie V, Plu-Bureau G, Conard J, Horellou MH, Canonico M, Scarabin PY. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011;18:488-493.
66. Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost 1994;71: 548-552.
67. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008;6:632-637.
68. Ramzi DW, Leeper KV. DVT and pulmonary embolism: Part I. Diagnosis. Am Fam Physician 2004;69:2829-2836.
69. RCOG(RoyalCollege ofObstetricians andGynaecologists). Venous thromboembolism and hormonal contraception. Green-top Guideline No. 40, 2010.
70. RCOG (Royal College of Obstetricians and Gynaecologists). Venous thromboembolism and hormone replacement therapy. Green-top Guideline No. 19, 3rd edition, 2011.
71. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010; 8:979-986.
72. Roeters van Lennep JE, Meijer E, Klumper FJCM, Middeldorp JM, BloemenkampKWM, Middeldorp S. Prophylaxis with low-dose low-molecular weight heparin during pregnancy and postpartum: is it effective? J Thromb Haemsot 2011;9: 473-480.
73. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353:1167-1173.
74. Rosendaal FR, van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003;1:1371-1380.
75. Rosfors S, Noren A, Hjertberg R, Persson L, Lillthors K, Torngren S. A 16-year haemodynamic follow-up of women with pregnancy-related medically treated iliofemoral deep venous thrombosis. Eur J Vasc Endovasc Surg 2001;22:448-455.
76. Rova K, Passmark H, Lindqvist PG. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril 2012;97:95-100.
77. Salomon O, Schiby G, Heiman Z, Avivi K, Sigal C, Levran D, Dor J, Itzchak Y. Combined jugular and subclavian vein thrombosis following assisted reproductive technology- new observation. Fertil Steril 2009;92:620-625.
78. Sassarini J, Lumsden MA. Hot flushes: are there effective alternatives to estrogen? Menopause Int 2010;16:81-88.
79. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362:428-432.
80. Severinsen MT, Kristensen SR, Johnsen SP, Dethlefsen C, Tjoønneland A, Overvad K. Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study. Circulation 2009;120:1850-1857.
81. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'FallonWM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-593.
82. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, Gavasso S, Huisman MV, Buller HR, Wouter ten Cate J et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999;81:198-202.
83. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005;118:978-980.
84. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56:141-146.
85. Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, Green J, Reeves GK., The MillionWomen Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost 2012;10:2277-2286. First published online October 30, 2012. doi:10.1111/j.1538-7836.2012.04919.x
86. The Writing Group for theWomen's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative. JAMA 2002;255:3243-3253.
87. Vandenbroucke JP, KosterT, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-1457.
88. van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous thromboembolism: where are we now? J Thromb Haemost 2011;9:257-266.
89. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339:b2921.
90. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010;30:2297-2300.
91. van Vliet HA, Tchaikovski SN, Rosendaal FR, Rosing J, Helmerhorst FM. The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC). Thromb Haemost 2009;101:691-695.
92. van Vlijmen EF, Veeger NJ, Middeldorp S, Hamulyak K, Prins MH, Buller HR, Meijer K. Thrombotic risk during oral contraceptive use and pregnancy inwomenwith factorV Leiden or prothrombin mutation: a rational approach to contraception. Blood 2011; 118:2055-2061.
93. Vieria CS, Ferriana RA, Garcia AA, Pinatoa MC, Azevedo GD, Gomez MK, Silva de-Sa MF. Use of the etonorestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod 2007;22:196-201.
94. VossenCY, Conard J, Fontcuberta J, Makris M, Van Der Meer FJ, Pabinger I, Palareti G, Preston FE, Scharrer I, Souto JC et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost 2004;2:1526-1532.
95. Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, Clement C, Robinson KS, Lewandowski B. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997;350:1795-1798.
96. Wells PS, Ginsberg JS, Anderson DR, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998;129:997-1005.
97. Westerlund E, Henriksson P, WallenH, Hovatta O, Wallberg KR, Antovic A. Detection of a procoagulable state during controlled ovarian hyperstimulation for in vitro fertilization with global assays of haemostasis. Thromb Res 2012;130:649-653.
98. WHO (World Health Organization). Medical eligibility criteria for contraceptive use, 4th edn. Geneva:World Health Organization, 2011.
99. Winkler UH, Howie H, Buhler K, Korver T, Geurts TBP, Coelingh Bennink HJT. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75mg desogestrel or 30mg levonorgestrel. Contraception 1998;57:385-392.